Tykerb 250 mg Lapatinib Tablets (1 pack / 30 tabs)

At a Glance

Generic Name: Lapatinib

Brand Name: Tykerb 250 mg

Strength & Pack Size: 250 mg tablets, 1 pack / 30 tablets

Dosage Form & Route: Oral film-coated tablets for swallowing whole

Therapeutic Class: Dual HER2/EGFR tyrosine kinase inhibitor (targeted therapy)

Primary Indications: HER2-positive advanced or metastatic breast cancer in selected patients, according to local label

Typical Use in Therapy: Combined with capecitabine or endocrine therapy after trastuzumab or where oral HER2-targeted therapy is appropriate

Mode of Action: Inhibits HER2 (ErbB2) and EGFR (ErbB1) signalling pathways that drive tumour growth and survival

Key Benefits: Oral targeted option that can delay disease progression and control symptoms in carefully selected HER2-positive breast cancer patients

Precautions: Requires monitoring of liver function, cardiac status, diarrhoea, skin reactions and adherence; used only under oncology supervision

Storage: Store in the original pack below 30 °C, protected from moisture and out of reach of children

Product Description

Tykerb 250 mg contains lapatinib, an oral dual tyrosine kinase inhibitor that targets HER2 and EGFR receptors involved in the growth and survival of certain breast cancer cells. It is used under specialist oncology supervision for HER2-positive advanced or metastatic breast cancer, typically in combination with capecitabine or with endocrine therapy in hormone receptor–positive, HER2-positive disease. Tykerb 250 mg lapatinib tablets provide an oral targeted option for patients where continued HER2 blockade remains an important part of the treatment strategy after prior trastuzumab or other systemic therapies.

Each pack of Tykerb 250 mg supplied by Generic Meds Mart contains 30 film-coated tablets, designed to be taken by mouth once daily in a regimen defined by the treating oncologist. Lapatinib therapy is usually part of a broader treatment plan that may include prior or concurrent chemotherapy, endocrine therapy, radiotherapy and HER2-directed monoclonal antibodies. Because of the complexity of HER2-positive metastatic breast cancer management, Tykerb 250 mg should never be started, stopped or adjusted without explicit instruction from the oncology team.

Generic Meds Mart sources Tykerb 250 mg lapatinib tablets only from licensed manufacturers and authorised distributors. Packs are supplied in original, sealed oncology packaging so that hospital or clinic pharmacies can confirm brand, strength, batch number and expiry before dispensing. Outer shipping cartons are neutral and do not reveal that the contents are breast cancer medicines, helping protect patient privacy. Pricing is displayed in USD, which can make planning for ongoing targeted therapy easier for patients and clinics coordinating long-term care.

Key Uses

Within the framework of local approvals and guidelines, Tykerb 250 mg lapatinib tablets are used for HER2-positive breast cancer that is advanced or metastatic and requires continued HER2-targeted therapy. Common situations include combination with capecitabine after progression on regimens containing trastuzumab, or use with an aromatase inhibitor or other endocrine therapy in hormone receptor–positive, HER2-positive advanced disease where an oral regimen is appropriate.

The exact place of Tykerb 250 mg in therapy depends on prior exposure to trastuzumab, pertuzumab, T-DM1 and other HER2-targeted agents, as well as access to newer treatments. Oncologists will weigh the benefits of lapatinib-based regimens against alternatives, considering tumour burden, sites of metastases, comorbidities, prior toxicities and patient preferences. Tykerb 250 mg lapatinib tablets are part of a personalised treatment plan rather than a one-size-fits-all solution.

How Lapatinib Works in Chemotherapy

Lapatinib, the active ingredient in Tykerb 250 mg, is a small-molecule tyrosine kinase inhibitor that targets the intracellular domains of HER2 (ErbB2) and EGFR (ErbB1) receptors. In HER2-positive breast cancer, overexpression or amplification of HER2 drives aggressive tumour growth through downstream signalling pathways that promote proliferation, survival and metastasis.

By selectively binding to and inhibiting HER2 and EGFR tyrosine kinase activity, lapatinib helps block these downstream pathways, including PI3K/AKT and MAPK signalling. This can slow tumour cell proliferation and may trigger apoptosis in HER2-dependent cancer cells. When combined with capecitabine or endocrine therapy, Tykerb 250 mg lapatinib tablets contribute to a multi-pronged strategy that targets both HER2 signalling and DNA replication or hormone-driven growth, depending on the partner agent.

Because lapatinib is an oral agent taken daily, its effect depends heavily on consistent dosing and adherence. Missed doses or treatment interruptions should be discussed with the oncology team so that risk and benefit can be reassessed in context.

Dosage & Administration

Tykerb 250 mg lapatinib tablets must be prescribed and monitored by an oncologist experienced in managing HER2-positive breast cancer. The total daily dose is typically calculated as a specific number of 250 mg tablets taken once daily, with or without food, according to the official product information and the chosen combination regimen. Tablets should be swallowed whole with water and should not be crushed or chewed.

Depending on the protocol, Tykerb 250 mg may be started several days before capecitabine or endocrine therapy or taken concurrently. Patients are usually advised to take lapatinib at the same time each day, under consistent dietary conditions, to reduce variability in exposure. Regular monitoring includes clinical assessment, blood tests (especially liver function tests) and, in some settings, cardiac evaluation such as echocardiography, given that HER2-targeted therapies can affect heart function. Any dose changes, temporary interruptions or treatment discontinuation are determined by the oncology team based on response and tolerability.

Precautions

Before starting Tykerb 250 mg lapatinib tablets, oncologists carefully review liver function, cardiac history, concurrent medicines, gastrointestinal health and potential drug interactions. Lapatinib can cause hepatotoxicity, diarrhoea, skin reactions and, less commonly, decreased left ventricular ejection fraction, so appropriate baseline assessments and ongoing monitoring are important.

Patients are usually advised to report persistent diarrhoea, signs of dehydration, yellowing of the skin or eyes, dark urine, marked fatigue, new or worsening shortness of breath, chest pain or palpitations. Drug–drug interactions must be reviewed, as lapatinib is metabolised via CYP3A4 and may be affected by or affect other medicines. Tykerb 250 mg lapatinib tablets are not recommended during pregnancy, and effective contraception is usually advised during treatment and for a period after stopping therapy. Breastfeeding is generally not recommended while on lapatinib.

Lapatinib Side Effects

Common side effects

Common lapatinib side effects seen with Tykerb 250 mg include diarrhoea, nausea, vomiting, abdominal discomfort, decreased appetite, fatigue, rash or dry skin, palmar-plantar discomfort when combined with capecitabine, and mild elevations in liver enzymes. Many patients also notice mild nail changes or hair thinning.

These effects are often manageable with anti-diarrhoeals, dose interruption or reduction, topical skin care, supportive medicines and careful hydration. The oncology team will provide written instructions on how to manage early diarrhoea and when to seek urgent assessment if symptoms worsen or do not improve.

Serious side effects

Less common but serious lapatinib adverse effects require immediate medical attention. These can include severe hepatotoxicity with significant liver enzyme elevation or jaundice, severe or persistent diarrhoea leading to dehydration and electrolyte disturbances, serious skin reactions, decreased left ventricular ejection fraction with symptoms of heart failure, and rare interstitial lung disease–like reactions.

Patients should seek urgent help if they develop intense, persistent diarrhoea, severe abdominal pain, marked jaundice, dark urine, sudden shortness of breath, chest pain, rapid weight gain with leg swelling, significant rash with blistering or peeling, or any other alarming symptom. The oncology team may need to interrupt Tykerb 250 mg, adjust the dose or switch to an alternative therapy depending on severity and causality.

Storage

Tykerb 250 mg lapatinib tablets should be stored in the original blister pack or bottle at a temperature recommended in the product information, typically below 30 °C, away from moisture and direct heat. The pack should be kept out of sight and reach of children and not transferred to unlabelled containers. Tablets must not be used after the expiry date printed on the carton and blister or bottle label. Unused or expired medicine should be returned to a pharmacy or disposed of according to local guidance for oncology medicines, not thrown in household waste.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to targeted oncology medicines such as Tykerb 250 mg lapatinib tablets. We work only with licensed manufacturers and authorised distributors that comply with recognised Good Manufacturing Practice and maintain traceable batch records. Each pack of Tykerb 250 mg supplied by Generic Meds Mart is delivered in sealed original packaging so your oncology pharmacy can verify brand, strength, batch number and expiry before dispensing.

Displaying prices in USD helps patients and clinics budget for ongoing HER2-positive metastatic breast cancer treatment, which often spans many months or longer. Orders are shipped in neutral outer packaging with no explicit reference to breast cancer or lapatinib, and tracking is provided where available so refills can be coordinated before existing supplies run out. Our role is logistical and informational; we do not replace the treating oncologist, and all clinical decisions about using Tykerb 250 mg lapatinib tablets remain strictly with your specialist team.

Order Now

Tykerb 250 mg lapatinib tablets are a targeted oncology medicine that must only be used as part of a clearly defined plan from an experienced oncologist. Before ordering Tykerb 250 mg from Generic Meds Mart, your team should have reviewed pathology reports confirming HER2-positive status, prior treatments, cardiac function and expected benefits and risks of lapatinib-based therapy. You should understand how Tykerb 250 mg will be combined with capecitabine or endocrine therapy, what daily dose you will take, how long each cycle lasts and what monitoring is required.

Once your regimen is agreed, your team can calculate how many packs of Tykerb 250 mg (1 pack / 30 tabs) are needed for your initial course. You can then select the required number of packs on Generic Meds Mart, add them to your cart and complete secure checkout in USD. Medicines are shipped in discreet packaging with full original labelling inside. You should never change, pause or stop Tykerb 250 mg lapatinib tablets without speaking to your oncology team, and any new or severe symptoms should be reported promptly so they can be evaluated in context.

FAQ about Tykerb (Lapatinib)

Q1: What is Tykerb 250 mg used for?
Tykerb 250 mg contains lapatinib, a dual HER2 and EGFR tyrosine kinase inhibitor used under specialist supervision for HER2-positive advanced or metastatic breast cancer, usually in combination with capecitabine or endocrine therapy according to local approvals and guidelines.

Q2: Is Tykerb 250 mg a chemotherapy tablet?
Tykerb 250 mg lapatinib tablets are a form of targeted therapy rather than traditional cytotoxic chemotherapy. They work by blocking HER2 and EGFR signalling pathways in cancer cells. However, they are still powerful anti-cancer medicines with important side effects and monitoring requirements, and they are often used together with chemotherapy or endocrine therapy.

Q3: How long will I need to take Tykerb 250 mg?
Duration of Tykerb 250 mg lapatinib treatment varies from patient to patient. Many people stay on lapatinib therapy as long as their disease is controlled and side effects are manageable. Treatment may be changed or stopped if the cancer progresses or if toxicity becomes unacceptable. Your oncology team will review response, imaging and tolerability regularly to decide how long to continue therapy.

Q4: What should I do if I miss a dose of Tykerb 250 mg?
If you miss a dose of Tykerb 250 mg, follow the instructions in your product leaflet or those provided by your oncology team. In general, you should not double the next dose to make up for a missed one. Instead, you may be told to take the next scheduled dose at the usual time and inform your team if missed doses occur frequently.

Q5: Can Tykerb 250 mg interact with other medicines or supplements?
Yes. Lapatinib is metabolised by liver enzymes such as CYP3A4 and can be affected by or affect certain prescription medicines, over-the-counter products and herbal supplements. Always tell your oncology team and pharmacist about everything you take, including acid-reducing medicines, antibiotics, antifungals, antivirals and herbal remedies, and never start or stop another medicine without checking for potential interactions.

Palbocib 125 mg Palbociclib Capsules (1 bottle / 21 caps)

At a Glance

Generic Name: Palbociclib

Brand Name: Palbocib 125 mg

Strength & Pack Size: 125 mg capsules, 1 bottle / 21 capsules

Dosage Form & Route: Hard gelatin capsules for oral use

Therapeutic Class: CDK4/6 inhibitor targeted therapy

Primary Indications: Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, in combination with endocrine therapy as per local label

Typical Patient Profile: Adults with HR-positive, HER2-negative breast cancer where CDK4/6 inhibition is appropriate based on specialist assessment

Mode of Action: Selectively inhibits cyclin-dependent kinases 4 and 6 to arrest cell-cycle progression in tumour cells

Key Benefits: Improved progression-free outcomes when combined with endocrine therapy in eligible patients, with an oral, at-home dosing schedule

Precautions: Requires regular blood count monitoring, assessment for infections, liver tests and effective contraception; use only under oncology supervision

Storage: Store in the original bottle below the temperature stated on the pack, tightly closed and protected from moisture, out of the reach of children

Product Description

Palbocib 125 mg contains palbociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with endocrine therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Rather than acting as classic cytotoxic chemotherapy, palbociclib is a targeted therapy designed to disrupt key cell-cycle regulators that drive uncontrolled proliferation in HR-positive breast cancer cells.

Each bottle of Palbocib 125 mg palbociclib capsules supplied by Generic Meds Mart contains 21 capsules, reflecting a standard 21-day “on treatment” period in a typical 28-day cycle when the medicine is used according to its approved schedule. The 125 mg strength is frequently chosen as the starting dose for many adults, with dose adjustments made by the treating oncologist if neutropenia or other side effects arise. Palbocib 125 mg is almost always prescribed alongside endocrine therapy such as an aromatase inhibitor or fulvestrant, forming a combination regimen that targets both hormonal signalling and cell-cycle control.

Generic Meds Mart sources Palbocib 125 mg palbociclib capsules only from licensed manufacturers and authorised distributors. Each bottle and outer carton displays the brand name, strength, generic name, batch number and expiry date so that oncology pharmacies can verify the medicine before dispensing. Parcels are shipped in neutral outer packaging without visible references to breast cancer or targeted therapy, supporting patient privacy while maintaining full traceability through invoices and batch documentation. Our role is limited to access and logistics; all treatment decisions remain with your oncology team.

Key Uses

Palbocib 125 mg palbociclib capsules are used as part of systemic therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, according to local prescribing information and guidelines. Typical uses include:

• Use with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women and other eligible adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
• Use with fulvestrant in patients whose disease has progressed after prior endocrine therapy, where a CDK4/6 inhibitor remains appropriate.
• Use in carefully selected patient groups where dual targeting of hormone signalling and CDK4/6-mediated cell-cycle pathways is expected to improve disease control compared with endocrine therapy alone.

Exact positioning of Palbocib 125 mg within the treatment pathway depends on prior therapies, menopausal status, comorbidities, tumour burden and local practice. The choice of partner endocrine therapy and sequencing relative to other systemic agents is always determined by a specialist.

How Palbociclib Works in Chemotherapy

Palbociclib, the active ingredient in Palbocib 125 mg, is a selective inhibitor of cyclin-dependent kinases 4 and 6. These kinases form complexes with D-type cyclins and play a central role in regulating transition from the G1 to S phase of the cell cycle, a checkpoint that determines whether a cell proceeds to DNA synthesis and division. In hormone receptor-positive breast cancer, CDK4/6 activity is often upregulated, contributing to uncontrolled proliferation.

By inhibiting CDK4 and CDK6, palbociclib reduces phosphorylation of the retinoblastoma (Rb) protein, a gatekeeper of G1-to-S progression. Reduced Rb phosphorylation keeps the cell-cycle checkpoint engaged, leading to G1 arrest and limiting proliferation of sensitive tumour cells. When combined with endocrine therapy that reduces or blocks estrogen-driven signalling, palbociclib helps slow tumour growth, delay progression and extend the duration of response in many patients with HR-positive, HER2-negative metastatic disease.

Dosage & Administration

Palbocib 125 mg palbociclib capsules must only be prescribed and monitored by oncologists experienced in treating advanced breast cancer with CDK4/6 inhibitors. The commonly used schedule is 125 mg taken once daily for 21 consecutive days, followed by 7 days off treatment, forming a 28-day cycle. Palbociclib is given alongside a companion endocrine therapy, which may be taken continuously or on its own schedule depending on the product used.

Capsules should be swallowed whole with water and should not be chewed, opened or crushed. Patients are usually advised to take Palbocib 125 mg at approximately the same time each day and to follow the instructions in the patient leaflet regarding food. If a dose is missed or vomited, patients should follow their oncologist’s or pharmacist’s advice rather than doubling the next dose. Before each cycle and at defined points during therapy, complete blood counts and other tests are performed. Dose reductions or interruptions may be required if neutropenia, thrombocytopenia or other toxicities reach predefined thresholds.

Precautions

Before starting Palbocib 125 mg, the oncology team will review the patient’s prior treatments, blood counts, liver function, concomitant medicines and infection risk. Palbociclib can cause clinically significant neutropenia, increasing susceptibility to infections, so patients should be educated about promptly reporting fever or signs of illness. Strong inhibitors or inducers of CYP3A may alter palbociclib exposure and often need to be avoided or managed carefully.

Effective contraception is strongly recommended for people of childbearing potential during palbociclib therapy and for a period after stopping, as palbociclib may harm a developing fetus. Breastfeeding is generally not recommended while taking Palbocib 125 mg. Patients should inform their care team about any planned procedures, new medicines or herbal supplements, and should never adjust their palbociclib dose without medical advice.

Palbociclib Side Effects

Common side effects

Common palbociclib side effects in patients taking Palbocib 125 mg include neutropenia and leukopenia, often detected on routine blood tests, as well as fatigue, nausea, decreased appetite, diarrhoea, constipation, mild stomatitis or mouth sores, hair thinning, low-grade infections, headache and mild elevations in liver enzymes. Many of these effects are manageable with supportive care, cycle-by-cycle monitoring and dose modifications. Patients are routinely counselled on infection precautions and when to seek urgent care.

Serious side effects

Serious palbociclib adverse effects require urgent medical attention and may include febrile neutropenia or severe infections, severe or persistent neutropenia, significant thrombocytopenia with bleeding, pronounced liver enzyme elevations, interstitial lung disease or pneumonitis, and very rare severe hypersensitivity reactions. Warning signs include high fever, chills, shortness of breath, persistent cough, chest pain, unexplained bruising or bleeding, dark urine, yellowing of the skin or eyes or severe fatigue and weakness. If any of these occur while using Palbocib 125 mg palbociclib capsules, emergency medical review is essential and treatment may need to be interrupted or adjusted.

Storage

Palbocib 125 mg capsules should be stored in the original bottle with the cap tightly closed, at or below the temperature stated on the carton, and protected from moisture. The bottle should be kept out of the sight and reach of children and should not be stored in the bathroom or other humid environments. Capsules must not be used after the expiry date on the label, and any unused or expired palbociclib should be returned to a pharmacy or disposed of via an approved medicines take-back programme, not in household waste or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart is dedicated to improving access to targeted oncology medicines such as Palbocib 125 mg palbociclib capsules for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. We work only with licensed manufacturers and authorised exporters that follow recognised quality standards and maintain documented batch traceability. Each bottle is supplied in sealed original packaging so that treating oncologists and pharmacy teams can confirm the product name, strength, batch number and expiry before advising patients.

All orders are processed in USD through secure checkout, and shipments are packed in discreet, neutral outer packaging that does not mention breast cancer or targeted therapy. Where available, trackable shipping options help patients and clinics coordinate refills so that palbociclib cycles can continue without unnecessary interruptions. Our role is limited to logistics and access; decisions about when to start, adjust or stop Palbocib 125 mg therapy remain entirely with your oncology specialists.

Order Now

Before ordering Palbocib 125 mg palbociclib capsules from Generic Meds Mart, you should have a clear treatment plan from your oncologist specifying that a CDK4/6 inhibitor combined with endocrine therapy is appropriate for your breast cancer and detailing the intended dose, cycle structure and monitoring schedule. Your team will explain the goals of therapy, expected time course of response, possible side effects and when to contact the clinic urgently.

Once this plan is in place, you can select Palbocib 125 mg (1 bottle / 21 caps), choose the number of bottles needed for your prescribed cycles and complete secure checkout in USD. Medicines will be dispatched in discreet packaging with documentation including product and batch details for your records and for your oncology pharmacy. You should never start, stop or change palbociclib dosing without specialist guidance, and any concerning symptom during treatment should be reported promptly so your team can adjust your care safely.

FAQ about Palbocib (Palbociclib)

Q1: What is Palbocib 125 mg used for?
Palbocib 125 mg contains palbociclib, a CDK4/6 inhibitor used in combination with endocrine therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, according to local prescribing information and oncology guidelines.

Q2: Is Palbocib 125 mg a form of chemotherapy?
Palbocib 125 mg is considered targeted therapy rather than traditional cytotoxic chemotherapy. It interferes with CDK4/6-mediated cell-cycle progression in cancer cells, but it is still a potent anticancer medicine and must be used under close specialist supervision with regular monitoring.

Q3: How long will I need to stay on palbociclib treatment?
Many patients remain on palbociclib-based therapy for as long as it continues to control the disease and side effects remain manageable. The optimal duration varies between individuals and depends on response, tolerability and the availability of alternative options. Only your oncology team can decide how long you should continue Palbocib 125 mg.

Q4: Can I miss or delay a dose of Palbocib 125 mg?
If you miss a dose or vomit after taking a capsule, you should follow the instructions from your oncologist or patient leaflet. In general, you should not double your next dose to make up for one that was missed. Any questions about missed doses or delays should be discussed with your care team, who may adjust your schedule if needed.

Q5: Do I need special blood tests while on Palbocib 125 mg?
Yes. Regular blood tests are an essential part of palbociclib therapy, especially to monitor white blood cell and neutrophil counts, platelets and liver function. These tests help your team decide whether it is safe to start a new cycle, whether dose adjustments are needed and how to manage any side effects that arise.

Hertab 250 mg Lapatinib Tablets (1 pack / 30 tabs)

At a Glance

Generic Name: Lapatinib

Brand Name: Hertab

Strength & Pack Size: 250 mg lapatinib per tablet; 1 pack / 30 tablets

Dosage Form & Route: Oral tablet, swallowed whole with water

Therapeutic Class: Tyrosine kinase inhibitor (EGFR/HER2 inhibitor), targeted anticancer therapy

Primary Indication: HER2-positive breast cancer in appropriate regimens

Usual Adult Dose: Total daily dose is commonly taken once daily as multiple 250 mg tablets, but the exact regimen is defined by your oncologist

Prescription Status: Prescription-only medicine

Storage: Store below 25–30 °C in original packaging, protect from moisture and light, keep out of reach of children

Product Description

Hertab 250 mg contains lapatinib, an oral targeted anticancer medicine used in adults with HER2-positive breast cancer when your oncology team determines it is appropriate. This product is supplied as 250 mg tablets in a 1 pack / 30 tabs presentation, designed to support planned therapy and structured monitoring. Lapatinib is not a general-purpose medicine and should only be used within a confirmed diagnosis and a specialist-led treatment plan.

In HER2-positive breast cancer, treatment decisions are individualized and may depend on whether the disease is advanced or metastatic, what therapies have been used before, and how the cancer is behaving on scans and laboratory assessments. Lapatinib is often used in combination regimens rather than as a stand-alone treatment, and your oncologist will explain the role of the medicine, the expected goals, and the monitoring schedule. Do not start, stop, or change the way you take Hertab 250 mg without medical supervision, and do not rely on general online information to replace a personalised oncology plan.

Generic Meds Mart supplies Hertab 250 mg lapatinib tablets in original manufacturer packaging sourced through licensed channels. The outer carton and blisters typically show the brand name, strength, active ingredient, batch number, and expiry date so your clinic or pharmacy can verify the product on receipt. Orders are packed in discreet outer parcels to support privacy, and delivery options are designed for international customers. If you are comparing options, confirm the correct strength and pack size with your care team before ordering and avoid making decisions based only on lapatinib price.

Key Uses

Hertab 250 mg lapatinib is used in HER2-positive breast cancer when inhibition of HER2-driven signalling is clinically appropriate and the patient’s overall treatment plan supports an oral targeted option. In advanced or metastatic settings, lapatinib may be used as part of a combination regimen selected by an oncologist, especially when a structured oral schedule is helpful for ongoing treatment coordination and monitoring.

Your oncology team will define whether lapatinib is being used alongside another anticancer medicine, how response will be assessed, and what symptoms or lab changes should trigger contact with the clinic. Because targeted therapy still carries meaningful risks, lapatinib treatment is typically paired with monitoring for side effects, interactions, and adherence to the planned schedule. Always follow your specialist’s instructions, and if you need to order lapatinib online, do so only after your regimen and follow-up plan are clearly confirmed.

How Lapatinib Works in Chemotherapy

Lapatinib works by inhibiting specific tyrosine kinases linked to tumour growth signals, particularly HER2 (ErbB2) and, in many cases, EGFR (ErbB1). In HER2-positive breast cancer, overactive HER2 signalling can drive uncontrolled cell growth and survival pathways. By blocking the intracellular kinase activity, lapatinib reduces downstream signalling that cancer cells use to proliferate and resist cell death, which can contribute to disease control when taken consistently within the prescribed regimen.

Because this mechanism is targeted signal inhibition rather than traditional DNA-damaging chemotherapy, lapatinib has a side-effect profile that differs from many classic cytotoxic agents. However, monitoring remains essential, and treatment may require supportive care, dose adjustments, or temporary interruption depending on tolerability. Your oncologist balances expected benefit with safety considerations such as gastrointestinal effects, liver function changes, and potential cardiac effects in susceptible patients.

Dosage & Administration

Hertab 250 mg tablets are taken by mouth exactly as prescribed by your oncologist. Lapatinib is commonly taken once daily as a total dose made up of multiple 250 mg tablets, and it may be scheduled in combination with other anticancer medicines depending on the protocol. Swallow tablets whole with water and do not crush or split them unless your clinic provides a specific instruction. Try to take the medicine at the same time each day to support consistent exposure and reliable monitoring.

Drug interactions can be clinically important with lapatinib. Some medicines can increase or decrease lapatinib levels in the body, including certain antibiotics, antifungals, anticonvulsants, and herbal products such as St John’s wort. Always share a complete list of prescription medicines, over-the-counter products, and supplements with your oncology team and pharmacist. Never self-adjust dosing, and if a dose is missed, follow your clinic’s guidance rather than taking extra tablets to “catch up.”

Precautions

Lapatinib can cause diarrhoea and dehydration, which may become serious if not managed early. Your oncology team may provide a plan for anti-diarrhoeal treatment, hydration, and when to contact the clinic. Liver function changes can occur, so scheduled blood tests are important even if you feel well. Report symptoms such as yellowing of the skin or eyes, dark urine, severe fatigue, or persistent abdominal pain promptly.

Cardiac effects such as reduced left ventricular ejection fraction can occur in some patients, particularly those with existing heart disease or other risk factors, so your oncologist may arrange baseline and follow-up heart monitoring when appropriate. Lung toxicity is uncommon but can be serious, so new or worsening shortness of breath, cough, or fever should be assessed urgently. Lapatinib may harm an unborn baby, so effective contraception is required during treatment, and pregnancy planning must be discussed with your specialist.

Lapatinib Side Effects

Common side effects

Common lapatinib side effects may include diarrhoea, nausea, vomiting, reduced appetite, abdominal discomfort, fatigue, headache, mouth soreness, and skin changes such as rash or dryness. Some patients notice soreness of hands or feet when lapatinib is combined with other agents, and blood tests may show liver enzyme changes that require monitoring. Many side effects can be managed with supportive care when reported early, but you should not change the dose on your own.

Serious side effects

Serious side effects require urgent medical attention and may include severe or persistent diarrhoea with dehydration, significant liver injury, new or worsening shortness of breath, chest pain, fainting, or signs of a clinically important heart problem. Severe skin reactions are rare but can occur, especially if accompanied by fever, blistering, or widespread pain. If you experience alarming symptoms, seek urgent medical care and tell clinicians you are taking lapatinib.

Storage

Store Hertab 250 mg tablets below 25–30 °C, protected from moisture and direct light, and keep them in the original blister packaging until use to reduce mix-ups and maintain stability. Keep all medicines out of reach of children and pets. Do not use tablets after the expiry date printed on the carton or blisters, and follow pharmacist guidance for safe disposal of unused or expired tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for specialty oncology medicines such as Hertab 250 mg lapatinib tablets. Products are supplied in original packaging sourced through licensed channels, with batch and expiry details visible to support verification by pharmacies and oncology teams. Pricing is shown in USD and orders are processed through secure checkout designed for international customers.

Shipments are packed in discreet outer packaging to support privacy and reduce unwanted attention to sensitive treatment needs. We do not replace your treating doctor or provide personalised medical decisions. Whether lapatinib is appropriate, how it should be combined with other medicines, and how side effects are managed must be determined by qualified oncology professionals.

Order Now

Before you buy Hertab 250 mg online from Generic Meds Mart, you should have a confirmed HER2-positive breast cancer diagnosis and a treatment plan agreed with your oncologist. Your care team will define the correct total daily dose, timing, combination regimen (if used), and the monitoring schedule for side effects and response. Once your plan is confirmed, select Hertab 250 mg (1 pack / 30 tabs), add it to your cart, and complete secure checkout in USD.

Do not start therapy on your own and do not stop or change dosing without medical guidance. If you develop severe diarrhoea, signs of liver problems, breathing difficulties, or symptoms that may suggest a heart issue, seek urgent medical care and inform clinicians that you are taking lapatinib.

FAQ about Hertab (Lapatinib)

Q1: What is Hertab 250 mg used for?

Hertab 250 mg contains lapatinib, an oral targeted medicine used in HER2-positive breast cancer when prescribed by an oncologist as part of an appropriate regimen and monitoring plan.

Q2: Is Hertab taken alone or with other medicines?

Lapatinib is often used in combination regimens in advanced or metastatic breast cancer, and your oncologist will explain which medicines are combined and why that approach fits your situation.

Q3: How do I take Hertab 250 mg tablets?

Hertab tablets are taken by mouth on the schedule prescribed by your oncologist, commonly once daily as multiple 250 mg tablets to reach the planned total dose. Swallow tablets whole with water and follow your clinic’s timing instructions.

Q4: What should I do if I get diarrhoea while taking lapatinib?

Diarrhoea can become serious, so contact your oncology team early for guidance on anti-diarrhoeal treatment, hydration, and when you need assessment. Do not self-adjust the dose without specialist advice.

Q5: What monitoring is usually needed during treatment?

Monitoring commonly includes clinical checks and blood tests, especially liver function, and sometimes heart monitoring depending on your risk factors and the full treatment regimen. Your oncologist will set the schedule.

Herduo 250 mg Lapatinib Tablets (1 pack / 30 tabs)

At a Glance

Generic Name: Lapatinib

Brand Name: Herduo

Strength & Pack Size: 250 mg per tablet; 1 pack / 30 tablets

Dosage Form & Route: Oral tablet, swallowed whole with water

Therapeutic Class: HER2/EGFR tyrosine kinase inhibitor, targeted anticancer therapy

Primary Indication: HER2-positive breast cancer where lapatinib-based therapy is appropriate

Usual Adult Dose: Often 1250–1500 mg daily depending on regimen, but dose and duration are defined by your oncologist

Prescription Status: Prescription-only medicine

Storage: Store below 25–30 °C in original packaging, protected from moisture and light

Product Description

Herduo 250 mg contains lapatinib, an oral targeted medicine used in adults with HER2-positive breast cancer when your oncology specialist determines it is suitable. Lapatinib is typically used for advanced or metastatic breast cancer in defined regimens, including combinations where a HER2-targeted approach is needed and treatment goals require long-term disease control. Herduo is supplied as 250 mg tablets in a 1 pack / 30 tabs presentation, supporting planned dosing and ongoing monitoring.

Unlike infusion-based biologic therapies, lapatinib is taken by mouth, but it still requires careful specialist oversight. Your oncologist considers tumour biology (including HER2 status), prior treatments, liver function, heart risk, drug interactions, and tolerability before choosing a lapatinib-containing plan. Herduo 250 mg is not a medicine to start, stop, or modify without medical guidance, and it should not be used as a substitute for specialist care.

Generic Meds Mart supplies Herduo 250 mg lapatinib tablets in original manufacturer packaging sourced through licensed channels. The carton and blisters typically show the brand name, strength, active ingredient, batch number, and expiry date so your pharmacy or clinic can verify the product on receipt. Orders are shipped in discreet outer packaging, pricing is displayed in USD, and delivery options support patients coordinating refills with oncology follow-up.

Key Uses

Herduo 250 mg lapatinib is used as part of specialist-led treatment plans for HER2-positive breast cancer, most often in advanced settings where targeted therapy is needed. Lapatinib may be used after progression on prior HER2-directed treatments, or as recommended by local guidelines for specific patient profiles.

Depending on the protocol, lapatinib may be combined with other anticancer medicines such as capecitabine, or used with endocrine therapy in hormone receptor-positive, HER2-positive disease when a dual approach is appropriate. The exact regimen, line of therapy, and monitoring schedule are defined by your oncologist, and therapy should be reviewed regularly to balance benefit and tolerability.

How Lapatinib Works in Chemotherapy

Lapatinib is a small-molecule tyrosine kinase inhibitor that targets the intracellular domains of HER2 (ErbB2) and EGFR (ErbB1). In HER2-positive breast cancer, HER2-driven signalling can promote tumour cell growth and survival. By inhibiting these kinases, lapatinib reduces downstream signalling through pathways involved in proliferation and resistance, which can contribute to disease control when the medicine is taken consistently as prescribed.

Because lapatinib acts on signalling rather than directly damaging DNA, its effect depends on sustained exposure and adherence to the dosing plan. This targeted mechanism also explains why the side effect profile differs from classic cytotoxic chemotherapy, although serious risks can still occur and require monitoring. Your oncology team may monitor liver tests, heart function where relevant, and symptoms suggesting toxicity or interactions.

Dosage & Administration

Herduo 250 mg tablets are taken by mouth exactly as prescribed by your oncologist. Total daily doses in lapatinib regimens are commonly in the range of 1250–1500 mg per day, which means multiple 250 mg tablets taken once daily, but the exact number of tablets, timing, and duration depend on the combination regimen and your individual factors.

Swallow tablets whole with water and take them at the same time each day. Follow your clinician’s advice on whether to take lapatinib with food or on an empty stomach, as administration instructions can affect absorption. Do not take extra tablets to make up for a missed dose unless your oncology team explicitly instructs you to do so.

Precautions

Lapatinib can affect the liver, and your oncologist may order baseline and periodic liver function tests during treatment. Contact your clinic urgently if you develop symptoms such as yellowing of the skin or eyes, dark urine, severe abdominal pain, or unusual fatigue. Lapatinib can also affect heart function in some patients, so new shortness of breath, swelling, chest discomfort, or palpitations should be assessed promptly.

Drug interactions matter. Some medicines can increase or decrease lapatinib levels, including certain antibiotics, antifungals, anticonvulsants, and herbal products such as St John’s wort. Always share a complete list of prescriptions, over-the-counter products, and supplements with your oncology pharmacist. Pregnancy should be avoided during therapy, and contraception planning should be discussed with your specialist.

Lapatinib Side Effects

Common side effects

Common lapatinib side effects may include diarrhoea, nausea, vomiting, loss of appetite, fatigue, rash or acne-like skin changes, mouth soreness, and hand–foot skin reactions when used with other medicines. Mild changes in liver tests can occur on monitoring. Tell your clinic early about diarrhoea or worsening skin reactions so supportive care can be started promptly and treatment interruptions can be avoided where possible.

Serious side effects

Serious side effects require urgent medical attention and may include severe or persistent diarrhoea with dehydration, significant liver injury, severe skin reactions with blistering or peeling, new or worsening shortness of breath, heart rhythm disturbances, or symptoms of reduced heart function. Signs of infection, high fever, confusion, fainting, or rapidly worsening symptoms should be treated as urgent. If you experience severe adverse effects, do not self-adjust the dose; contact your oncology team immediately for instructions.

Storage

Store Herduo 250 mg in the original packaging below 25–30 °C, protected from moisture and direct light. Keep medicines out of reach of children and do not use tablets after the expiry date printed on the pack. If you are travelling or coordinating shipments, keep tablets in the labelled blister or bottle to avoid mix-ups and to support verification by your clinic.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for specialty oncology medicines such as Herduo 250 mg lapatinib tablets. Products are supplied in original packaging sourced through licensed distributors with batch and expiry details to support verification. Orders are processed via secure checkout, pricing is displayed in USD, and shipments are packed in discreet outer cartons.

International delivery and tracking options help patients coordinate refills around oncology appointments and monitoring schedules. Generic Meds Mart does not replace your treating doctor. Decisions about whether lapatinib is appropriate, how long to use it, and how to manage side effects must be made by qualified healthcare professionals.

Order Now

Before you buy Herduo 250 mg lapatinib tablets online from Generic Meds Mart, you should have a confirmed HER2-positive diagnosis and a treatment plan agreed with your oncologist. Your care team will advise which tests are needed and how often, and they will review interaction risks with your current medicines. Once your plan is confirmed, select Herduo 250 mg (1 pack / 30 tabs), add it to your cart, and complete secure checkout in USD with discreet delivery.

Do not start therapy on your own, and do not stop or change dosing without medical guidance. If you develop severe diarrhoea, signs of liver injury, chest symptoms, or a serious skin reaction, seek urgent medical care and inform clinicians that you are taking lapatinib.

FAQ about Herduo (Lapatinib)

Q1: What is Herduo 250 mg used for?

Herduo 250 mg contains lapatinib, a targeted HER2/EGFR inhibitor used in adults with HER2-positive breast cancer when prescribed by an oncology specialist as part of a defined regimen.

Q2: How many tablets do I take per day?

Lapatinib regimens typically use a total daily dose that requires multiple 250 mg tablets, but the exact number depends on the protocol and combinations your oncologist has chosen.

Q3: Can Herduo be combined with other anticancer medicines?

Yes. Lapatinib is often used with other medicines such as capecitabine or endocrine therapy in appropriate patients, and the combination should be managed by your oncology team with regular monitoring.

Q4: What should I do if I miss a dose?

If you miss a dose, take the next dose at the usual time and do not take extra tablets unless your oncology team specifically instructs you to. If you miss more than one dose, contact your clinic for guidance.

Q5: What monitoring is usually needed during treatment?

Monitoring often includes clinical review for diarrhoea and skin reactions and blood tests such as liver function tests, with additional checks for heart function where relevant, based on your specialist’s plan.